Joint Pain Injections Market Analysis

Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, Others)

Based on product, hyaluronic acid injections segment is set to account for joint pain injections market share of more than 68.9% by the end of 2037. This is majorly due to their effectiveness in providing long-term relief in the knee joint. In January 2018, OrthogenRx, Inc. launched TriVisc (sodium hyaluronate) treating osteoarthritic (OA) knee pain for people who fail to receive adequate relief from painkillers and physical therapies. Increasing regulatory approvals from governments of various regions, growing awareness of its benefits among the patients, and a shift towards viscosupplementation over corticosteroids due to fewer side effects further boost their demand.

Joint Type (Knee, Hip, Hand & Wrist, Others)

Based on joint type, the knee segment is anticipated to register steady growth during the forecast period in the joint pain injections market. The segment is driven by a high prevalence of osteoarthritis, increased physical activity levels, and rising obesity rates. In September 2024, Sun Pharma and Moebius Medical Limited received U.S. FDA Fast Track designation (FTD) approval for MM-II for treating osteoarthritis knee pain. Data from a randomized, controlled, Phase 2b study showcased that a single intra-articular injection of 3mL offered better pain relief in comparison to a placebo for up to 26 weeks. Advancements in injection therapies, including hyaluronic acid and platelet-rich plasma, provide targeted relief, driving their adoption for knee treatments.

Our in-depth analysis of the global market includes the following segments: